UVB effects on genes of those with and without Psoriasis
Narrow-band Ultraviolet B Treatment Boosts Serum 25-hydroxyvitamin D in Patients with Psoriasis on Oral Vitamin D Supplementation
ACTA Dermato-Venereologica doi: 10.2340/00015555-1685
Meri J. Ala-Houhala, Toni Karppinen, Katja Vähävihu, Hannu Kautiainen, Yvonne Dombrowski, Erna Snellman, Jürgen Schauber, Timo Reunala
Department of Dermatology, Tampere University Hospital, FIN-33521 Tampere, Finland
A course of treatment with narrow-band ultraviolet B (NB-UVB) improves psoriasis and increases serum 25-hydroxyvitamin D (25(OH)D). In this study 12 patients with psoriasis who were supplemented with oral cholecalciferol, 20 µg daily, were given a course of NB-UVB and their response measured. At baseline, serum 25(OH)D was 74.14 ± 22.9 nmol/l. At the 9th exposure to NB-UVB 25(OH)D had increased by 13.2 nmol/l (95% confidence interval (95% CI) 7.2–18.4) and at the 18th exposure by 49.4 nmol/l (95% CI 35.9–64.6) above baseline. Psoriasis Area Severity Index score improved from 8.7 ± 3.5 to 4.5 ± 2.0 (p < 0.001). At baseline, psoriasis lesions showed low vitamin D metabolizing enzyme (CYP27A1, CYP27B1) and high human β-defensin-2 mRNA expression levels compared with those of the healthy subjects. In conclusion, NB-UVB treatment significantly increases serum 25(OH)D in patients with psoriasis who are taking oral vitamin D supplementation, and the concentrations remain far from the toxicity level. Healing psoriasis lesions show similar mRNA expression of vitamin D metabolizing enzymes, but higher antimicrobial peptide levels than NB-UVB-treated skin in healthy subjects.

Fig. 2.
(A) CYP27A1 mRNA,
(B) CYP27B1 mRNA and
(C) cathelicidin mRNA
expression levels in skin lesions of patients with psoriasis (n = 12) and normal skin of healthy subjects (n = 13) before and at 9th (after) narrow-band ultraviolet B (NB-UVB) exposure.
Before NB-UVB course the CYP27A1 and CYP27B1 levels are significantly lower (p < 0.001), but the cathelidicin levels do not differ (p = 0.34) in the patients with psoriasis compared with the healthy subjects.
NB-UVB exposure did not change CYP27A1 mRNA, CYP27B1 mRNA or cathelidicin mRNA levels in the patients with psoriasis (A: p = 0.17; B: p = 0.070; C: p = 0.88) but the decrease is significant (A: p< 0.001; B: p = 0.002; C: p< 0.001) in the healthy subjects.
PDF is attached at the bottom of this page
See also VitaminDWiki
Psoriasis category listing with associated searches
items in CYP27B1 category
Pages listed in BOTH Psoriasis AND UV
{category}